Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with the F508del/Unknown Genotype

Version 1 : Received: 28 May 2021 / Approved: 31 May 2021 / Online: 31 May 2021 (10:11:41 CEST)

How to cite: Comegna, M.; Terlizzi, V.; Salvatore, D.; Colangelo, C.; Di Lullo, A.M.; Zollo, I.; Giovanni, T.; Castaldo, G.; Amato, F. Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with the F508del/Unknown Genotype. Preprints 2021, 2021050728 (doi: 10.20944/preprints202105.0728.v1). Comegna, M.; Terlizzi, V.; Salvatore, D.; Colangelo, C.; Di Lullo, A.M.; Zollo, I.; Giovanni, T.; Castaldo, G.; Amato, F. Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with the F508del/Unknown Genotype. Preprints 2021, 2021050728 (doi: 10.20944/preprints202105.0728.v1).

Abstract

The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 12 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the other allele. However, there is a group of patients, in addition to those with rare mutations, in which despite the presence of a F508del in one allele, it was not possible to identify any mutation in the other allele. Today these patients are excluded from treatment with Trikafta. In Italy CF patients carrying F508del/unknown represent about 3% (156 patients) of the overall Italian CF patients. In this paper we show that the Trikafta treatment of nasal epithelial cells, derived from F508del/Unknown patients, results in a significant rescue of CFTR activity. Based on our findings, we think that the F508del/Unknown patients considered in this study could obtain clinical benefits from Trikafta treatment, and we strongly suggest their eligibility for this type of treatment.This study, adding further evidence in the literature, once again confirms the validity of functional studies on nasal cells in the cystic fibrosis theratyping and personalized medicine.

Subject Areas

theratyping; cystic fibrosis; functional characterization; personalized medicine; CFTR; rare mutation

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.